Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_assertion type Assertion NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_head.
- NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_assertion description "[T-cell therapy is one such area where recent trials using T cells genetically modified to express an antibody-based chimeric antigen receptor (CAR) targeted against the CD19 antigen have demonstrated impressive responses when adoptively transferred to patients with advanced chronic lymphocytic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_provenance.
- NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_assertion evidence source_evidence_literature NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_provenance.
- NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_assertion SIO_000772 24329792 NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_provenance.
- NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_assertion wasDerivedFrom befree-20150227 NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_provenance.
- NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_assertion wasGeneratedBy ECO_0000203 NP833705.RA674kA0U04A6lykZuqMRU0kDRiqBWNVMUQi5sQ0u-zB0130_provenance.